Skip to main content
. 2021 Aug 18;113(12):1683–1692. doi: 10.1093/jnci/djab124

Table 1.

Clinical and tumor characteristics of patients with early-onset and average-onset colorectal cancer

Characteristic EO-CRC, ≤35 years (n = 151) EO-CRC, 36-49 years (n = 608) AO-CRC (n = 687) ≤35 years vs AO
36-49 years vs AO
P a q P a q
Age at diagnosis, y
 Mean (SD) 30.8 (3.8) 43.8 (3.8) 62.1 (8.5)
 Median (range) 31 (14-35) 44 (36-49) 61 (50-93)
Sex, No. (%)
 Male 74 (49) 347 (57.1) 370 (53.9) .28 .26
 Female 77 (51) 261 (42.9) 317 (46.1)
Race, No. (%)
 White 113 (74.8) 475 (78.1) 561 (81.7) .07 0.266 .13 0.204
 Black or African American 11 (7.3) 29 (4.8) 46 (6.7) .86 0.858 .15 0.204
 Asian or Indian subcontinent 14 (9.3) 59 (9.7) 40 (5.8) .14 0.266 .01 0.046
 Other 13 (8.6) 45 (7.4) 40 (5.8) .20 0.266 .26 0.263
BMI, No. (%)
 Normal 81 (53.6) 233 (38.3) 211 (30.7) <.001 <0.001 .006 0.023
 Underweight 4 (2.6) 13 (2.1) 11 (1.6) .33 0.325 .54 0.539
 Overweight 39 (25.8) 192 (31.6) 248 (36.1) .02 0.023 .08 0.155
 Obese 25 (16.6) 168 (27.6) 211 (30.7) <.001 <0.001 .22 0.294
 Unknown 2 (1.4) 2 (0.4) 6 (0.9)
Median BMI 24.3 26.5 27.0 <.001 .07
Smoking history, No. (%)
 Ever 25 (16.6) 194 (31.9) 310 (45.1) <.001 <.001
 Never 124 (82.1) 414 (68.1) 367 (53.4)
 Unknown 2 (1.3) 0 (0) 10 (1.5)
Hypertension, No. (%)
 Yes 2 (1.3) 69 (11.3) 300 (43.7) <.001 <.001
 No 148 (98) 531 (87.3) 385 (56)
 Unknown 1 (0.7) 8 (1.4) 2 (0.3)
Diabetes, No. (%)
 Yes 4 (2.6) 33 (5.4) 80 (11.6) <.001 <.001
 No 146 (96.7) 574 (94.4) 605 (88.1)
 Unknown 1 (0.7) 1 (0.2) 2 (0.3)
Family history of CRC, No. (%)
 Yes 74 (49) 306 (50.3) NA
 No 76 (50.3) 295 (48.5) NA
 Unknown 1 (0.7) 7 (1.2) NA
Stage, No. (%)
 I 2 (1.3) 22 (3.6) 29 (4.2) .10 0.131 .67 0.668
 II 12 (7.9) 53 (8.7) 93 (13.5) .08 0.131 .006 0.025
 III 47 (31.1) 165 (27.1) 161 (23.4) .06 0.131 .14 0.28
 IV 90 (59.7) 368 (60.6) 404 (58.9) .93 0.927 .53 0.668
Primary tumor location, No. (%)
 Cecum 15 (9.9) 39 (6.4) 120 (17.5) .02 0.091 <.001 <0.001
 Ascending colon 9 (6) 37 (6.1) 80 (11.6) .04 0.123 <.001 <0.001
 Hepatic flexure 1 (0.7) 11 (1.8) 23 (3.3) .10 0.184 .08 0.125
 Transverse colon 6 (4) 18 (3) 30 (4.4) 1.00 1.000 .19 0.209
 Splenic flexure 5 (3.3) 18 (3) 9 (1.3) .15 0.227 .05 0.092
 Descending colon 9 (6) 41 (6.7) 39 (5.7) .85 0.956 .49 0.489
 Sigmoid 47 (31.1) 197 (32.4) 160 (23.3) .06 0.139 <.001 <0.001
 Rectosigmoid 8 (5.3) 41 (6.7) 60 (8.7) .19 0.243 .18 0.209
 Rectum 51 (33.7) 205 (33.7) 155 (22.6) .007 0.061 <.001 <0.001
 Colon, NOS 0 (0) 1 (0.2) 11 (1.6)
Metastasectomy, No. (%)
 Yes 78 (51.7) 280 (46.1) 338 (49.2) .41 .69
 No 68 (45) 303 (49.8) 348 (50.7)
 Unknown 5 (3.3) 25 (4.1) 1 (0.1)
Molecular subtype, No. (%)
 MSS 139 (92.1) 583 (95.8) 626 (91.1) .87 0.873 <.001 <0.001
 MSI 8 (5.3) 21 (3.5) 56 (8.2) .31 0.464 <.001 <0.001
 POLE 4 (2.6) 4 (0.7) 5 (0.7) .06 0.182 1.00 1.000
Tumor grade (MSS only), No. (%)b
 Well differentiated 1 (0.7) 10 (1.7) 1 (0.2) .34 0.344 .005 0.016
 Moderately differentiated 116 (83.5) 454 (77.9) 477 (76.2) .34 0.344 .72 0.827
 Poorly differentiated 22 (15.8) 114 (19.6) 122 (19.5) .28 0.344 .83 0.827
 Unknown 0 (0) 5 (0.8) 26 (4.1)
Symptoms
 BRBPR 62 (41.1) 249 (41.0) 178 (25.9) <.001 0.002 <.001 <0.001
 Abdominal pain, bloating, pelvic pain 56 (37.1) 207 (34.0) 184 (26.8) .01 0.049 .005 0.011
 Change in bowel habits 36 (23.8) 114 (18.8) 188 (27.4) .42 0.626 <.001 <0.001
 Weight loss 12 (7.9) 40 (6.6) 66 (9.5) .64 0.803 .07 0.099
 Anemia 3 (2.0) 22 (3.6) 100 (14.6) <.001 <0.001 <.001 <0.001
 Fatigue 3 (2.0) 25 (4.1) 47 (6.9) .02 0.064 .04 0.072
 Screening colonoscopy 3 (2.0) 17 (2.8) 33 (4.8) .18 0.338 .08 0.105
 Upper GI symptoms 3 (2.0) 8 (1.3) 26 (3.8) .34 0.558 .005 0.011
 Rectal pain 22 (15.8) 114 (19.6) 122 (19.5) .28 0.344 .83 0.827
 Back, shoulder, bone pain 1 (0.7) 12 (2.0) 6 (0.9) 1.00 1.00 .10 0.117
 Obstruction 0 (0.0) 4 (0.7) 13 (1.9) .14 0.302 .08 0.105
a

A 2-sided Fisher exact test was used. AO = average-onset; BMI = body mass index; CRC = colorectal cancer; EO = early-onset; GI = gastrointestinal; MSI = microsatellite instability; MSS = microsatellite stable; NA = not available; NOS = not otherwise specified; POLE = polymerase epsilon; BRBPR = bright red blood per rectum.

b

For tumor grade, only MSS tumors were compared, given that MSI tumors are known to be associated with a higher prevalence of poorly differentiated tumors (35 years and younger, n = 139; 36-49 years, n = 583; AO, n = 626). For classification of tumor grade, tumors were categorized according to the most aggressive differentiation exhibited within any given tumor.